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Abstract
Summary To evaluate the incidence of new and/or progres-
sive vertebral deformities and changes in bone mineral
density, we re-examined 66 patients with sarcoidosis after a
follow-up period of four years. In 17 subjects (26%) new
and/or progressive vertebral deformities were found, though
BMD did not change significantly.
Introduction Previous studies from our group have shown
that morphometric vertebral deformities suggestive of
fractures can be found in 20% of patients with sarcoidosis,
despite a normal bone mineral density (BMD). The aim of
this study was to determine the incidence of new and/or
progressive vertebral deformities and the evolution of BMD
during the course of this disease.
Methods BMD of the hip (DXA) and vertebral fracture
assessment (VFA) with lateral single energy densitometry
was performed at baseline and after 45 months in 66
patients with sarcoidosis. Potential predictors of new/
progressive vertebral deformities were assessed using logis-
tic regression analysis.
Results The BMD of the total group was unchanged after
follow-up. The prevalence of vertebral deformities in-
creased from 20 to 32% (p<0.05); in 17 subjects (26%)
new or progressive vertebral deformities were diagnosed. A
lower T-score of the femoral neck [(OR=2.5 (CI: 1.0-5.9),
p<0.05)] and mother with a hip fracture [(OR=14.1
(CI:1.4-142.6), p<0.05)] were independent predictors of
new/progressive deformities.
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Introduction
Sarcoidosis is a T-cell driven chronic inflammatory
disease. Although chronic inflammation has been associ-
ated with decreased bone mineral density as a result of
the effects of cytokines on bone metabolism [1–4], we
and others could not demonstrate changes in BMD in
subjects with this condition, even if treated with glucocorti-
coids (GCs). In a cross-sectional study of 124 subjects with
sarcoidosis, BMD values similar to an age- and sex-
matched reference population were found [5]. Comparable
observations were made in three small studies in untreated
patients [6–8]. These studies also found a normal BMD
relative to age and sex-matched controls, except for a small
group of postmenopausal women in which BMD was
moderately decreased at the spine in longstanding sarcoid-
osis only [7].
Although in our cross-sectional study normal BMD
values were observed, increased levels of the bone
resorption marker serum carboxy-terminal cross-linked
telopeptide of type I collagen (ICTP) and the bone
formation marker serum procollagen type I amino-terminal
propeptide (PINP) suggestive of increased bone turnover
were found [5]. ICTP levels correlated with markers of
disease activity such as soluble IL-2 receptor (sIL2R) and
angiotensin converting enzyme (ACE). In addition, verte-
bral deformities suggestive of fracture were demonstrated in
20% of the subjects studied in this series. This may imply
that the fracture risk in sarcoidosis is increased due to an
increased bone turnover with consequent changes in
microarchitecture and decrease of bone strength which is
not reflected by changes in BMD [9, 10].
If so, this may result in progressive vertebral deformities
during the course of the disease. For this reason we re-
examined individuals with sarcoidosis four years after the
initial measurements to determine the incidence of new and/
or progressive vertebral deformities and their relation with
changes in BMD.
Subjects and methods
Subjects
Sixty-six of the 124 subjects with sarcoidosis that were
studied in 2002 [5] agreed to participate in the follow-up
study performed in 2006. None of the 56 subjects who
declined or were unable to participate had impaired
mobility or a history of vertebral fractures. The mean age
of this group was 45 years and did not differ with respect to
gender or glucocorticoid (GC) use from the group of
subjects that were re-examined in 2006.
Demographic, clinical and treatment data of the subjects
studied in 2002 and 2006 are summarized in Table 1. The
group consisted of 22 pre-menopausal women, 11 post-
menopausal women, and 33 men; median age of the total
group (all Caucasian) was 43 years (20–66 y). The clinical
records of all patients were reviewed. In 2002 patients were
evaluated according to a standard protocol that included
questionnaires, measurement of height and weight, lung
function, measurement of BMD, a single energy densitom-
etry of the spine, and laboratory evaluation [5]. In 2006 the
same protocol was repeated. Informed consent was
obtained from all participants and the study was approved
by the medical ethics committee of our institution.
Pulmonary evaluation
Lung function measurements, including forced expiratory
volume in one second (FEV1) and forced vital capacity
(FVC), were measured with a pneumotachograph. The
diffusion capacity for carbon monoxide (DLCO) was
measured using the single-breath method (both Masterlab,
Jaeger, Würzburg, Germany). Values were expressed as a
percentage of those predicted [11].
Chest radiographs were graded according to the radio-
graphic staging of DeRemee (0 to III), adding stage IV, the
end stage of lung fibrosis [12, 13]. All interpretations were
made by a radiologist who was blinded to the patient’s
history.
Laboratory assays
Serum 1,25-dihydroxyvitamin D concentration was deter-
mined by radioimmuno-assay using a commercially avail-
able kit [(IDS Ltd, Boldon, England, interassay coefficient
of variation (IE-CV) 18%, intra-assay CV (IA-CV) 15%)].
High-sensitivity C-reactive protein (hs-CRP) was measured
by particle-enhanced immunonephelometry on the BN
Prospec (Dade Behring). The detection limit is 0.175 mg/L
840 Osteoporos Int (2008) 19:839–847and the measuring range is 0.175–1100 mg/L. Soluble IL-2
receptor (sIL-2R) was determined on the IMMULITE au-
tomated analyzer, by means of a two-site chemiluminescent
enzyme immunometric assay with a measuring range of 50–
7500 kU/L (Diagnostic Product Corporation, Los Angeles,
CA, cat no LKIP1). Serum angiotensin converting enzyme
(ACE) was measured using a colorimetric method. The
precision of the ACE assay was < 5.6% and the reference
interval for ACE was 9–25 U/L.
As a marker for bone formation, serum procollagen type
I amino-terminal propeptide (PINP) was measured. As a
marker for bone resorption, serum carboxy-terminal cross-
linked telopeptide of type I collagen (ICTP) was assessed.
Both PINP (IE-CV 3.2%, IA-CV 2.5%, lowest detectable
concentration 0.4 μg/l) and ICTP (IE-CV 3.5%, IA-CV
2.3%, lowest detectable concentration <0.1 μg/l) were
measured using commercial RIA kits (Orion Diagnostica
Oy, Espoo, Finland). To adjust for age and gender Z-scores
for these bone markers were obtained using a Dutch
reference group (300 women, 150 men), checked for
normal BMD of the lumbar spine and femur and normal
25-hydroxyvitamin-D levels [14, 15].
Table 1 Baseline and follow-up demographic, clinical, and treatment variables (n=66)
Variable Baseline (n=66) Follow-up (n=66) P*
Demographic variables
Female sex 33 (50%)
Postmenopausal 11 (17%) 14 (21%) ns
Age, years 43 (20–66)
Body mass index, kg/m
2 26.9±5.7 27.2±5.3 ns
Smoking 7 (11%)
Daily dietary calcium intake, mg 740 (110–2360) 758 (150–1340) ns
Clinical variables
Disease duration, years 3 (1–22) 7 (5–26)
Chest X-ray stage (0-I-II-III-IV) 24/11/12/16/3 27/5/12/15/7 ns
FEV1,% of predicted 87±28 91±26 ns
DLCO,% of predicted 87±16 92±18 ns
Physical activity 8.6±3.7 8.1±3.7 ns
Laboratory values (in serum)
Calcium, mmol/l (2.1–2.6) 2.4±0.1 2.4±0.08 ns
1,25(OH)2D3, nmol/l (0.040–0.200) 0.14±0.03
ACE, U/l (9–25) 22.5±9.8 15.3±7.9 0.001
sIL-2R, kU/l (241–846) 654 (188–4315)
Hs-CRP, mg/l (<10) 3.2 (0.2–191) 2.0 (1–16) <0.05
Z-score ICTP 0.7±1.4
Z-score PINP −0.1±0.9
Treatment variables
GC use never 31 (47) 26 (39) ns
GC use previous 14 (21) 25 (38) <0.01
GC use current 21 (32) 15 (23) ns
Lifetime GC dose, mg 9240 (200–48750) 11187 (200–56700) <0.001
Daily dose, mg 12.4±6.2 10.5±3.3 <0.05
Started on bisphosphonates after baseline measurement 6 (9)
Clinical risk factors for osteoporosis
Fracture 2 (2/24=8%) 5 (5/28=18%) ns
Low body weight (< 60 kg) 8 (12) 7 (11) ns
Severe immobilization 0 0 ns
Low physical activity index ≤ 5 18 (27) 18 (27) ns
Mother with hip fracture 6 (9) 7 (11) ns
Data are given as mean ± SD, median (range) or number (%); *=p value between baseline and follow-up measurement. Reference parameters in
brackets
Abbreviations: GC, glucocorticoid; FEV1, forced expiratory volume in one second; DLCO, diffusion capacity for carbon monoxide; 1,25(OH)
2D3, 1,25 dihydroxyvitamin D; ACE, angiotensin converting enzyme; sIL-2R, soluble interleukin-2 receptor; Hs-CRP, high-sensitivity C-reactive
protein; ICTP, carboxy-terminal cross-linked telopeptide of type I collagen; PINP, procollagen type I amino-terminal propeptide
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Bone mineral density (BMD) was measured by dual X-ray
absorptiometry (DXA, Hologic QDR 4500). In 2002 only the
BMD of the hip was measured. In 2006 the BMD of both the
hip and of the lumbar spine were determined. As reference
group for the hip the NHANES III database (sex- and age-
matched) was used. A standard protocol as described
previously was used for measurement of BMD. To adjust
for age and gender, Z-scores were used. To examine changes
in Z-scores between baseline and follow-up measurements a
Δ Z-score was calculated reflecting the difference between
the Z-score at follow-up and the Z-score at baseline.
Furthermore, after bone density measurement a lateral
single energy densitometry of the thoracic and lumbar spine
for vertebral fracture assessment (VFA) was performed
(also called Morphometric X-ray absorptiometry (MXA))
[16]. The scans obtained were analyzed twice by one
trained operator (intra-observer correlation: 0.85), using the
semi-quantitative method of Genant [17]. In addition we
measured every vertebra quantitatively. The observer was
blinded to the T-score values and to the values of the first
set of measurements. After visual examination six points
were placed on each vertebral body from T4 to L4. From
these points three vertebral heights were measured anterior
(Ha), mid (Hm) and posterior (Hp). On the basis of the
average score of these morphometric measurements, ratios
were calculated and a prevalent vertebral deformity was
defined as a reduction of height of 20% or more (Ha/Hp;
Hm/Hp and Hp/Hp below). Severity of deformities was
assessed using the scoring system of Genant [17]. A score
of ‘0’ was assigned to normal, non-fractured vertebra; ‘1’
for a mild deformity (20–25% reduction in anterior, middle
or posterior vertebral height); ‘2’ for a moderate deformity
(25–40% reduction) and ‘3’ for a severe deformity (>40%
reduction). A new vertebral deformity was scored if a
normal vertebra (grade 0) became deformed (grade ≥ 1) and
a progressive deformity if the grade increased [17].
Questionnaires
Calcium intake of all patients was scored in 2002 as well as
2006 on the basis of a detailed dietary list. Known clinical
risk factors for osteoporosis (weight below 60 kg, mother
with hip fracture, history of fractures after age 50, meno-
pausal status and severe immobilization) as well as daily
activities and exercise were assessed by a validated ques-
tionnaire [18], in which sports, daily and work activities are
scored with a minimum of zero and a maximum of
eighteen. GC therapy was evaluated by means of a patient
questionnaire and verified using all the records of the
patient’s pharmacist. It was scored as never, previous or
current use and if subjects were currently using GCs, the
daily dose was noted.
Statistics
Student t-tests, chi-square tests, and one-way ANOVAs
were used, depending on the variables and subgroups
tested. Depending on the analysis, change scores or actual
scores were used. Patients with new and/or progressive
vertebral deformity were clustered for the multivariate and
the receiver-operating characteristics (ROC) analysis. Mul-
tivariate logistic regression analyses was performed to
assess the strength of association between the incidence of
new and/or progressive vertebral deformities and gender,
age, weight, clinical risk factors, GC use, lifetime GC dose,
daily GC dose, disease activity, bone markers, calcium
intake, physical activity and BMD measurements. The
variables that were entered in the multivariable analysis
were those variables that appeared related (p<0.10) to this
outcome measure in univariate analyses. Odds ratio (OR)
Table 2 BMD variables at
baseline and follow-up for the
total group (n=66, median
follow-up duration 45 months
(range 35–49 months)
Abbreviations: BMD, bone
mineral density
P*=p value between baseline
and follow-up measurement
Variable Baseline measurement Follow-up measurement P*
BMD, mean ± SD gm/cm2
Femoral neck 0.84±0.12 0.83±0.12 ns
Trochanter 0.74±0.13 0.74±0.12 ns
Total hip 0.97±0.13 0.98±0.14 ns
Lumbar spine 1.04±0.14
Z-score, mean ± SD
Femoral neck 0.17±1.0 0.23±1.1 ns
Trochanter 0.27±1.1 0.32±1.1 ns
Total hip 0.18±1.0 0.32±1.0 0.001
Lumbar spine 0.03±1.4
T-score, mean ± SD
Femoral neck −0.42±1.0 −0.46±1.0 ns
Trochanter −0.02±1.1 −0.03±1.0 ns
Total hip −0.14±1.0 −0.10±1.0 ns
Lumbar spine −0.50±1.3
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using SPSS version 12.0. ROC analysis was used to assess
the ability of various levels of the T-score femoral neck to
predict the incidence of a new and/or progressive vertebral
deformity. The ROC curve indicates the probability of a
true-positive result as a function of the probability of a
false-positive result for all possible threshold values [19]. A
p value < 0.05 was considered statistically significant.
Results
Bone mineral density and bone turnover parameters
The results of BMD measurements are shown in Table 2.
The BMD of the total group remained unchanged after a
median follow-up of 45 months (range 35–49 months).
When stratifying patients according to GC use, no decrease
in each of the subgroups was found. Patients that never
used GCs showed a Δ Z-score of the femoral neck (FN) of
0.03±0.36 and a Δ Z-score of the trochanter of −0.08±
0.37. In patients with previous use of GCs these Δ Z-scores
were 0.10±0.36 and 0.22±0.43, respectively. Even the
group currently on GCs revealed no decrease of Z-score (Δ
Z-score FN: 0.06±0.30 and Δ Z-score trochanter: 0.00±
0.18) and also the subgroup of postmenopausal women
(n=11) did not show significant bone loss (Δ Z-score FN:
0.06±0.45 and Δ Z-score trochanter: −0.05±0.52). In the
total group, bone turnover parameters at baseline showed
an increased Z-score of ICTP compared to norm scores
(0.7, 95% confidence interval (CI):0.4–1.1; p<0.001). on
the other hand, the marker of bone formation (Z-score
PINP) did not differ from the reference population.
Clinical fractures and vertebral deformities
Three new non-vertebral fractures occurred during the
follow-up period. These included a hip fracture (twice in
the same patient), an ankle fracture and a fracture of the
thumb. All these fractures were related to trauma and
occurred in subjects older than 50 years.
Morphometric data are summarized in Table 3. In 2002
vertebral deformities (ratio of <0.80) were found in 19
vertebrae of 13 subjects. Seventeen of these were wedge
and two biconcave deformities. No crush deformities were
seen. The majority of these deformities were found in the
low thoracic region. At follow-up a new vertebral deformity
was scored if a normal vertebra (grade 0) became deformed
(grade ≥ 1) and a progressive deformity if the grade
increased [17]. With this method, 36 vertebral deformities
were found in 21 subjects. In one subject a vertebral
deformity (ratio 0.78 of T11) found in 2002 was not found
at follow-up (ratio 0.81). So, in total nine new subjects
revealed one or more vertebral deformities, which means an
increase of vertebral deformities from 20 to 32% of the
subjects studied (p<0.05). From the 21 subjects with a
vertebral deformity in 2006, 17 subjects (26% of total
group) were diagnosed with one or more new or progres-
sive vertebral deformities and in four subjects the deformity
was unchanged compared to baseline. Data on number and
severity of the deformities can be found in Table 3. Six
patients were started on a bisphosphonates after baseline
measurement and from these six patients, two had a new or
progressive vertebral deformity at follow-up.
Comparing the groups with and without new or
progressive vertebral deformities at follow-up, no differ-
ences in Δ Z-scores of BMD of the trochanter or femoral
neck (FN) were found (Δ Z-score trochanter −0.02±0.41
and 0.08±0.38 respectively and Δ Z-score FN 0.01±0.32
and 0.08±0.35). In addition no differences in baseline Z-
scores of ICTP and PINP were seen between these groups.
Multivariable logistic regression analysis, including factors
that correlated in the univariate analysis, revealed that a T-
score of the femoral neck at baseline (OR per 1 SD T-score
reduction=2.5 (CI: 1.0–5.9), p=0.04), and a mother with a
hip fracture (OR=14.1 (CI:1.4–142,6), p=0.02) were
determinants of a new and/or progressive morphometric
vertebral deformity at follow-up measurement. Factors such
as age, gender, calcium in take, GC use, daily GC dose,
lifetime GC dose, disease activity, bone markers, radio-
graphic stage and disease duration at baseline did not
predict new and/or progressive vertebral deformities.
The threshold level of the T-score FN that maximized the
combined specificity and sensitivity on the ROC curve
(Fig. 1)w a s<−0.45 for predicting a new and/or progressive
deformity (sensitivity 88%, specificity 51%).
Discussion
In this cohort of subjects with sarcoidosis, a high prev-
alence of morphometric vertebral deformities suggestive of
fracture was found, as well as a substantial increase in
vertebral deformities during a follow-up period of four
Table 3 Number and grade of deformities
Baseline Follow-up
No. of subjects with deformity 13 (20%) 21 (32%)*
No. of deformities
Mild 17 28
Moderate 2 8
Severe 0 0
Total 19 36
*P<0.05 between number of subjects with deformity at baseline and
follow-up
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vertebral deformities according to the criteria of Genant
[17], which increased to 32% of all subjects in 2006. In
parallel, the total number of deformities in these subjects
almost doubled. However, BMD of the trochanter and
femoral neck did not change over time and BMD of the
lumbar spine at follow-up measurement did not differ from
the reference population. These data are suggestive of an
increased risk of progressive vertebral deformities in
individuals with sarcoidosis despite preservation of BMD.
Although data on prevalent or incident fractures in
younger healthy populations are lacking, data from other
studies suggest that the incidence and prevalence of
vertebral deformities in this population are indeed high.
Prevalence rates of 30% asymptomatic vertebral fractures
are demonstrated in elderly post-menopausal women on
chronic GC therapy using the same techniques [20]. In a
previous study in 60 subjects (mean age 49±13 years) with
differentiated thyroid carcinoma we found vertebral defor-
mities in 7% of patients [21]. Data from the European
Vertebral Osteoporosis Study (EVOS), a very large cross-
sectional population based study on European subjects aged
50 to 79 years, showed a prevalence of vertebral deformi-
ties of 12% (range 6–21%) in males and females [22]. In
the Rotterdam study, in which 3469 men and women aged
55 years and older were studied, the prevalence of vertebral
deformity suggestive of fracture was 6.9% in men and 7.5%
in women [23]. The epidemiology of vertebral fractures in
women aged 50–54 years turned out to vary in different
countries from 4.7% – 11.5% [24]. All these studies
indicate that the fracture risk in subjects with sarcoidosis
is substantial, regardless the differences in populations
studied and differences in methodology.
A new vertebral deformity was found in 15 subjects
(23%). To identify incident deformities several approaches
can be followed. Measurement of changes in vertebral
heights of the same vertebral body from a baseline to a later
radiograph in which a decrease in height of 15 or 20% or
4 mm is suggestive of fracture [25, 26], changes in indices
of vertebral area [27] or changes in the number or presence
of prevalent deformities [17, 28]. Black and coworkers
evaluated these different approaches and concluded that
none of these were consistently better than any other
method [29]. As we aimed to assess the change of numbers
of subjects with one or more vertebral deformities over time
we used the last method [17], in which changes in number
of prevalent deformities are scored. A comparable approach
was followed in the European Prospective Osteoporosis
Study (EPOS) [30], which revealed an incidence of new
deformities of 3.4% after a similar follow-up period. As the
mean age of subjects included in this study was substan-
tially higher than that of our cohort, these data cannot be
used as a reference, although it is likely that in younger age
groups even lower incident deformities would be observed.
The high prevalence of vertebral deformities at baseline, the
significant increase of more than 50% of subjects after
follow-up with one or more deformity and the increase of
severity of prevalent deformities all imply that sarcoidosis
is a relevant risk factor for vertebral deformity.
What is the underlying mechanism of this predisposition
to vertebral deformities in view of the lack of effects on
BMD in sarcoidosis? The load bearing capacity of bone,
also referred to as ‘whole bone strength’, depends on the
amount of bone, the spatial distribution of the bone mass,
and the intrinsic properties of the materials that comprise
the bone. Thus, properties at the cellular, matrix, micro- and
Fig. 1 ROC curve using
Femoral neck T-score
to identify patients with new
and/or progressive vertebral
deformity. Area under the curve
(AUC): 0.72. Arrow: The
threshold level of T-score FN
that maximized combined
specificity and sensitivity was
< −0.45 (sensitivity 88%,
specificity 51%)
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properties of bone [31, 32]. Apparently, in sarcoidosis
mechanisms are involved that influence bone strength
without having a significant impact on bone mass. As we
found in the total group an increased marker of bone
resorption (Z-score ICTP) at baseline, one of the possible
mechanisms could be increased bone remodelling with a
negative effect on bone micro-architecture that is not
reflected by a change in BMD. It is well known that
chronic inflammatory diseases influence bone physiology
by the production of cytokines stimulating bone turnover
[1, 2, 33]. Increased bone remodelling is associated with an
increased bone fragility and thus fracture risk [34, 35] and
in postmenopausal women the level of bone turnover
turned out to be an as strong and independent predictor of
fractures as BMD [36, 37]. These data may support the
hypothesis that the chronic inflammatory state in sarcoid-
osis results in increased bone remodelling with a negative
effect on bone strength and thus an increased fracture risk.
No changes in BMD in the group currently treated with
GCs were found. This is unexpected as GCs are known to
effect BMD via several mechanisms with consequent
decrease of BMD. It may well be that this is due to
intermittent GC use, as most of our patients were on
intermittent glucocorticoids. Other studies have demonstrat-
ed that intermittent GC use has no major effects on BMD
[38]. A recent large retrospective cohort study on clinical
fracture risk among patients from the UK General Practice
Research Database showed that intermittent use of high
dose of oral GCs was associated with only a small increase
in the risk of osteoporotic fractures [39].
Despite the on average normal BMD, we found T-score
of the femoral neck and a family history of hip fractures to
be predictors of a new and/or progressive vertebral
deformity. This suggests that the combination of a lower
BMD in combination with the increased bone turnover in
sarcoidosis predisposes to progressive vertebral deformity.
If so, this would mean that in these high risk individuals
preventive treatment should be considered to reduce
fracture risk. Controlled trials are needed, however, to
substantiate this suggestion.
One of the limitations of our study is the lack of an age
and sex matched control population. Unfortunately data on
vertebral deformities in younger populations are at present
not available. The aim of this study was, however, not to
compare sarcoidosis patients with healthy subjects, but to
follow a cohort of these patients and to compare follow-up
with baseline measurements. Another limitation is the use
of morphometric X-ray absorptiometry (MXA) instead of
spine radiographs. MXA is less reliable for the detection of
deformities at the upper thoracic spine, where deformities
are less frequent as compared to the lumbar and mid-
thoracic spine. A recent study comparing MXA with lateral
spine X-ray found that vertebral morphometry using MXA
allowed diagnosis of vertebral fracture in the lumbar and
mid thoracic spine, where vertebral fractures are most
common [40]. The advantage of MXA is the low dose of
radiation and the convenience of the technique for patients.
The present quality of the images, with ongoing refinement
of this technology, is considered sufficient to be used for
the diagnosis of vertebral deformity consistent with fracture
[41]. Furthermore there is a lack of a “gold standard” for
VFA. We followed the method of Genant [17], which is
based on a reduction of the ratios of anterior, middle or
posterior heights and all measurements were performed
twice to improve accuracy. This is the simplest and most
practical method [42] and an association with future
fracture risk is documented [43, 44]. The above mentioned
EVOS study, however, applied the methodology described
by McCloskey and Eastell and co-workers in which
measurements are corrected for normal variations in
vertebral shape [25]. Relative to the method of Genant,
the method of Eastell [25] or McCloskey [28] may have
resulted in lower prevalences of vertebral deformities. This
does not, however, explain the differences in prevalence of
vertebral deformities reported elsewhere and in this paper.
The restrictions of the methodology are also the limited
ability to provide a differential diagnosis for the detected
deformities, a lower sensitivity for milder fractures and the
inability to evaluate the uppermost thoracic levels. Other
disorders that may cause changes in vertebral shape involve
congenital abnormalities and conditions as severe osteoar-
thritis [45] and Scheuermann’s disease. We have, however,
no indications that these relatively rare conditions may have
interfered with our observations.
In conclusion, we have shown that in subjects with
sarcoidosis the number of vertebral deformities, diagnosed
with morphometric assessment, increases during the course of
this disease despite preservation of BMD. Although this is an
uncontrolled study, it appears that subjects with sarcoidosis
have an increased fracture risk, even if BMD is normal. High
risk individuals can be identified by a low-normal BMD and
byafamilyhistoryofhipfractures.Probablytheseindividuals
will benefit from therapies that increase bone strength. A T-
score FN below −0.45 may be used to identify these
individuals with a high sensitivity and an acceptable specific-
ity. Studies evaluating the effects of such therapies in
individuals with sarcoidosis are however clearly needed.
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